Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01241903
Recruitment Status : Completed
First Posted : November 16, 2010
Results First Posted : June 24, 2014
Last Update Posted : March 28, 2017
Information provided by (Responsible Party):
Susan Smyth, University of Kentucky

Brief Summary:
The central hypothesis for this work is that platelet - leukocyte interactions play a critical role in the pathogenesis of acute ischemic events. The primary objective of the study is to determine if early, high-dose administration of the HMG-CoA reductase inhibitor rosuvastatin in the setting of acute coronary syndrome and percutaneous coronary intervention exerts beneficial vascular effects by reducing platelet - leukocyte interactions.

Condition or disease Intervention/treatment Phase
Acute Coronary Syndrome Angioplasty, Transluminal, Percutaneous Coronary Hydroxymethylglutaryl-CoA Reductase Inhibitors Blood Platelets Drug: rosuvastatin Drug: placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Early Use of Rosuvastatin (Crestor) in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
Study Start Date : June 2011
Actual Primary Completion Date : August 2013
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Experimental: Crestor Drug: rosuvastatin
Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
Other Name: crestor

Placebo Comparator: sugar pill Drug: placebo
frequency and duration

Primary Outcome Measures :
  1. Platelet - Leukocyte Aggregates [ Time Frame: within first 24 hours ]
    measured by flow cytometry

Secondary Outcome Measures :
  1. Biomarkers of Platelet Function and Myocardial Necrosis [ Time Frame: up to 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must be between 18 and 80 years old.
  2. Subjects must be willing and able to give informed consent
  3. A woman of child-bearing potential who is currently sexually active must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for up to 30 days after enrollment.
  4. Subjects must have symptoms of acute coronary syndrome as defined by 2 of the 3: (a) history of cardiac-ischemia-related symptoms of at least 10 minutes duration ≤ 8 hours prior to randomized treatment assignment (b) concurrent biomarker evidence of cardiac ischemia, as defined by troponin I or T greater that upper limit of normal (ULN) or creatine kinase-myocardial band (CK-MB) greater than ULN. (c) concurrent electrocardiographic evidence of cardiac ischemia, as defined by new of presumably new ST-segment depression (≥1 mm) or transient (<30 min) ST-segment elevation (≥ 1mm) in at least two contiguous leads.
  5. Subjects must be statin naive or currently only on low dose statin (Simvastatin 20mg, Pravastatin 40mg, or Atorvastatin 10mg)

Exclusion Criteria:

  • Age <18 years
  • Age > 80 years
  • Use of Crestor in the past 30 days
  • GFR (estimated) <30 ml/min
  • Hemodialysis
  • History of liver failure
  • Unexplained liver function abnormalities
  • Current or planned use of cyclosporine or gemfibrozil
  • Sepsis
  • Hypotension
  • Dehydration
  • Trauma
  • Severe metabolic, endocrine or electrolyte abnormality
  • Recent (within the last 2 weeks) or planned (in the next month) major surgery
  • HIV/AIDS with current of planned use of HIV protease inhibitors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01241903

United States, Kentucky
University of Kentucky Dept of Cardiology
Lexington, Kentucky, United States, 40536
Sponsors and Collaborators
Susan Smyth
Principal Investigator: Susan S Smyth, MD, PhD University of Kentucky

Responsible Party: Susan Smyth, Principal investigator, University of Kentucky Identifier: NCT01241903     History of Changes
Other Study ID Numbers: 10-208-F1V
First Posted: November 16, 2010    Key Record Dates
Results First Posted: June 24, 2014
Last Update Posted: March 28, 2017
Last Verified: February 2017

Keywords provided by Susan Smyth, University of Kentucky:
Platelet activation
platelet leukocyte aggregates

Additional relevant MeSH terms:
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors